Background: The respiratory syncytial virus (RSV) is a major cause of hospitalisation in young Inuit children. Prophylaxis with palivizumab is routinely recommended for premature infants and those with severe pulmonary or cardiac diseases. In the fall 2016, the Quebec Ministry of Health expan …
Date de publication (Zotero)
décembre, 2020
URL (Zotero)
https://pubmed.ncbi.nlm.nih.gov/32191589/?dopt=Abstract